Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

ABSTRACT:

SUBMITTER: Tewari KS 

PROVIDER: S-EPMC5714293 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature